NCT04316117

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2020-09-15Est. Completion: 2027-08-31

Enrollment target: 138 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
UCSF Medical Center-Mission Bay, San Francisco, California, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States
Bayhealth Hospital Kent Campus, Dover, Delaware, United States
GenesisCare USA - Aventura FP, Aventura, Florida, United States
Grady Health System, Atlanta, Georgia, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States
Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States

Anatomic Stage IV Breast Cancer AJCC v8Breast CarcinomaHER2-Negative Breast CarcinomaHormone Receptor-Positive Breast Carcinoma

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a me…

Fairbanks, United StatesEst. completion Jul 31, 2027

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Positive Breast CarcinomaInvasive Breast Carcinoma

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/c…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.